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Abstract: The central nervous system (CNS) may be involved by a variety of inflammatory diseases of blood vessels. 
These include primary angiitis of the central nervous system (PACNS), a rare disorder specifically targeting the CNS  
vasculature, and the systemic vasculitides which may affect the CNS among other organs and systems. Both situations  
are severe and convey a guarded prognosis. PACNS usually presents with headache and cognitive impairment. Focal 
symptoms are infrequent at disease onset but are common in more advanced stages. The diagnosis of PACNS is difficult 
because, although magnetic resonance imaging is almost invariably abnormal, findings are non specific. Angiography has 
limited sensitivity and specificity. Brain and leptomeningeal biopsy may provide a definitive diagnosis when disclosing 
blood vessel inflammation and are also useful to exclude other conditions presenting with similar findings. However, 
since lesions are segmental, a normal biopsy does not completely exclude PACNS. Secondary CNS involvement by  
systemic vasculitis occurs in less than one fifth of patients but may be devastating. A prompt recognition and aggressive 
treatment is crucial to avoid permanent damage and dysfunction. Glucocorticoids and cyclophosphamide are recom-
mended for patients with PACNS and for patients with secondary CNS involvement by small-medium-sized systemic 
vasculitis. CNS involvement in large-vessel vasculitis is usually managed with high-dose glucocorticoids (giant-cell   
arteritis) or glucocorticoids and immunosuppressive agents (Takayasu’s disease). However, in large vessel vasculitis, 
where CNS symptoms are usually due to involvement of extracranial arteries (Takayasu’s disease) or proximal portions of 
intracranial arteries (giant-cell arteritis), revascularization procedures may also have an important role.  
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1. INTRODUCTION 
  The central nervous system (CNS) vasculature may be 
targeted by an heterogeneous group of inflammatory dis-
eases. In its isolated, primary form, angiitis of the CNS 
(PACNS) is a rare form of vasculitis of unknown etiology 
primarily affecting small and medium sized vessels supply-
ing the brain parenchyma, spinal cord and leptomeninges [1-
3]. PACNS results in signs and symptoms of CNS dysfunc-
tion with no clinically apparent participation of other organs. 
The CNS may also be targeted, among other territories, by 
systemic vasculitides [4, 5]. This review will focus on diag-
nostic and therapeutic aspects of PACNS and secondary 
CNS involvement by systemic vasculitides in adulthood. 
Primary and secondary CNS vasculitis in childhood have 
been addressed in excellent recent reviews [6-8]. 
2. PRIMARY CNS VASCULITIS 
2.1. Epidemiology 
  Because of the rarity of PACNS and the absence of de-
finitive diagnostic tests, epidemiologic studies are virtually 
inexistent. An annual incidence of 2.4 per million people has 
been recently estimated in North America [9]. PACNS has 
been reported in children [6-8] and in the elderly. However,  
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it appears to be more frequent in males in their fourth and 
fifth decades of life [2, 9]. PACNS may represent 1.2% of 
vasculitis involving the CNS [3]. 
2.2. Pathogenesis  
  The pathogenesis of PACNS is unknown. Similar to 
other chronic inflammatory or autoimmune diseases, PACNS 
is thought to be triggered by infection. Cytomegalovirus,   
Ebstein-Barr virus, varicella-zoster virus, human immuno- 
deficiency virus, mycoplasma and chlamydia have been con-
sidered given the ability of these agents to produce vasculitic 
lesions [10-15]. However, in the majority of patients with 
PACNS a potential relationship with these or other infectious 
agents cannot be demonstrated.  
  The granulomatous nature of the vascular inflammatory 
lesions in most cases suggests a Th1-mediated response [3, 
16]. Th1-related cytokines may promote vascular inflamma-
tion in PACNS as suggested by several experimental models. 
Intracerebral injections of interferon-gamma have been 
shown to trigger inflammatory lesions and vasculitis in rats. 
[17]. Tumor necrosis factor (TNF) and interleukin-6 pro-
inflammatory functions may also contribute to vascular in-
flammation in PACNS [18, 19]. TNF/TNF receptor p75 
transgenic mice develop multifocal CNS ischemic injury 
secondary to vasculitis [18]. Elevated CSF IL-6 has been 
found in 3 patients with different types of vasculitis (polyar-
teritis nodosa, temporal arteritis and Behcet's disease) in-
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ology of PACNS is very limited delaying progress in the 
diagnosis and management of affected patients. 
2.3. Pathology 
  PACNS typically involves small-medium sized arteries 
and veins, especially those located in leptomeninges and 
subcortical areas. The characteristic histopathologic findings 
consist of inflammatory infiltration of vessel walls by T 
lymphocytes and activated macrophages which undergo 
granulomatous differentiation with giant-cell formation [3, 
16]. Inflammatory cells infiltrate the adventitia and subse-
quently progress through the artery wall causing fragmenta-
tion of the internal elastic lamina. Intimal proliferation and 
fibrosis leading to vascular occlusion is frequently observed 
[3, 16] (Fig. 1). This granulomatous pattern is the most 
commonly seen and led to the previously used term granu-
lomatous angiitis of the CNS [3, 16, 20]. However, granulo-
matous features may not be always observed and some 
specimens disclose the so-called atypical CNS angiitis pat-
terns consisting in predominantly lymphocytic infiltrates 
(lymphocytic pattern), necrotizing vasculitis with fibrinoid 
necrosis (necrotizing pattern) or mixed patterns [20]. In some 
cases, B lymphocytes and plasma cells can also be observed 
[21]. Vascular  amyloid deposits may be found in a subset 
of patients [20].  
  Although most patients with PACNS present primarily 
with CNS dysfunction, necropsy studies may disclose   
clinically asymptomatic vasculitis in additional locations 
including lungs, kidneys and gastrointestinal tract [3, 5, 16].  
Distinction from systemic vasculitis with prominent CNS 
involvement may be sometimes difficult to establish.  
2.4. Clinical Manifestations 
  Depending on the areas of the brain involved, PACNS 
may convey a wide variety of clinical findings. Moreover, 
disease severity and rapidity of progression may be highly 
variable among patients, increasing heterogeneity in clinical 
presentation. 
  In the largest series reported including 101 patients [9], 
the median age at diagnosis was 47 years (range 17-84 
years). The majority of patients presented with subacute 
manifestations of diffuse CNS dysfunction. Acute presenta-
tion was highly unusual. The most common initial symptoms 
were headache (63%) and cognitive impairment (50%). 
Headaches were initially of low intensity and progressively 
worsened. Cognitive impairment was also insidious. Focal 
symptoms usually appeared later in the course of the disease 
and included hemiparesis (44%), stroke (40%), aphasia 
(28%), transient ischemic attack (28%), ataxia (19%), sei-
zures (16%), dysarthria (15%) and blurred vision or de-
creased visual acuity (11%). Infrequent manifestations, oc-
curring in less than 10% of patients, included intracranial 
hemorrhage, amnesic syndrome, spinal cord manifestations 
such as paraparesis o quadriparesis, parkinsonism, vertigo, 
dizziness or cranial nerve palsy. Most patients had multiple 
manifestations. Other published series report similar findings 
[22, 23].  
  In order to facilitate clinical recognition and early diag-
nosis, clinical manifestations have been grouped in three 
major phenotypes: 1) Acute or more commonly subacute 
encephalopathy, presenting as a confusional syndrome with 
progression to stupor and coma; 2) Disease presentation re-
sembling atypical multiple sclerosis with a variety of focal 
symptoms such as optic neuropathy, brain stem episodes, 
seizures, headaches, encephalopathic episodes or hemi-
spheric stroke-like events and 3) Intracranial mass lesions, 
with headache, drowsiness, focal signs and elevated intracra-
nial pressure [24, 25].  
   It has also been suggested that predominant involvement 
of small versus medium-sized vessel may influence disease 
presentation. Small-vessel PACNS manifests as a subacute 
or acute encephalopathy with persistent headaches, cognitive 
impairment, confusion, and seizures. MRI usually discloses 
marked meningeal contrast enhancement whereas angiogra-
phy may not reveal changes because the affected vessels are 
small, beyond the detection threshold [26, 27]. This form of 
PACNS may respond to glucocorticoid monotherapy but 
25% of patients relapse. In contrast, when medium-size ves-
sels are involved, in addition to headaches and general CNS 
dysfunction, focal neurologic deficits and stroke are more 
common and angiography is more likely to reveal vascular 
abnormalities [9, 26, 27]. Four clinical features are associ-
ated with an increased mortality in patients with PACNS: 
focal neurological deficit, cognitive impairment, cerebral 
infarction and involvement of larger vessels [9].  
  General symptoms and findings suggesting some extent 
of systemic involvement may occur. Fever, weight loss, 
livedo reticularis, rash, peripheral neuropathy, arthritis and 
night sweats may be recorded in 20% of patients [2, 9].  
2. 5. Diagnosis 
  The diagnosis of PACNS is a challenge because of the 
lack of highly sensitive and specific diagnostic tests. Clini-
cal, analytical, neuroimaging, and histopathologic data are 
important, both in supporting the diagnostic suspicion and in 
excluding other conditions which may present with similar 
features. 
2.5.1. Laboratory Test Abnormalities  
  Routine laboratory tests are frequently within the normal 
range [2, 9, 28]. In some patients features of systemic   
inflammatory response including anemia, leukocytosis and 
moderately increased acute phase reactants (ESR, C-reactive 
protein and platelet counts) can be observed [2, 9]. Labora-
tory tests are useful to rule out other diseases which may 
present with similar symptoms such as infection, systemic 
vasculitis, malignancy, drug abuse and hypercoagulability 
states [5, 28, 29]. 
  Cerebrospinal fluid (CSF) is abnormal in 80-90% of pa-
tients [9]. Increased protein concentration is the most com-
mon finding. In a series of 101 patients, mean CSF protein 
concentration was 7 gr/L (range 1.5-10.3 gr/L) [9]. Pressure 
is increased in 50% of patients and elevated lymphocyte 
counts may be observed in 50-80%. CSF oligoclonal immu-
noglobulins may be found in up to 50% of individuals with 
PACNS [5, 23]. CSF pleocytosis is modest, rarely exceeding 
250 cells/μL. Higher leukocyte counts and the presence of 
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for possible infection [2]. CSF analysis is useful to exclude 
infection and malignancy and appropriate bacterial and fun-
gal stains, viral polymerase chain reactions, and flow cy-
tometry studies should be performed. 
2.5.2. Imaging 
2.5.2.1. Magnetic Resonance Imaging (MRI) and Magnetic 
Resonance Angiography (MRA) 
  MRI is sensitive but not specific in revealing changes 
associated with PACNS [30]. Lesions are frequently multiple 
and bilateral and include parenchymal or meningeal enhanc-
ing areas, ischemic areas or infarcts in the cortex, deep white 
matter, or periventricular white matter (Fig. 1A). It may also 
disclose hemorrhagic lesions [31, 32]. The sensitivity of 
MRI in biopsy-proven PACNS is very high, disclosing   
abnormalities in 97% of cases [22, 32-34] but abnormal   
findings are non specific. Diffusion weighted imaging is 
highly sensitive in detecting diffusion abnormalities and may 
be useful in patients with normal MRI [35]. MRA has lim-
ited sensitivity and is only able to disclose abnormalities in 
the largest intracranial vessels. The same limitations apply to 
CT-angiography [33, 34].  
2.5.2.2. Conventional Angiography 
   Conventional angiography is the most specific imaging 
technique for the diagnosis of PACNS and, compared to 
MRA is able to detect abnormalities in smaller vessels. 
Typical angiographic features of PACNS include multiple 
“beading” or segmental narrowing in large, intermediate, or 
small arteries with interposed regions of ectasia or normal 
luminal architecture [31-33] (Fig. 1D). Beading may be 
smooth or irregular and typically occurs bilaterally. Addi-
tional changes include aneurysms, collateral flow, isolated 
areas of vessel narrowing in multiple branches, circumferen-
tial or eccentric vessel irregularities, multiple occlusions 
with sharp cutoffs, and apparently avascular mass lesions 
[31-33].  
  Although findings from CNS conventional angiograms 
may support the diagnosis of PACNS and can be used to 
direct the site of biopsy, none of these findings alone is diag-
nostic because similar images can be present in other dis-
eases (Tables 1 and 2) [2, 5, 22, 28, 36-38].  
  Although essential for diagnosis, angiography has limited 
sensitivity and specificity. Patients with biopsy-proven 
PACNS may have normal appearing angiograms and, con-
versely, biopsies of angiographically abnormal vessels have 
been reported as normal [2, 5, 28]. The sensitivity of   
angiography in detecting PACNS ranges from 20% to 90% 
[1, 9, 31, 35, 37, 38] and specificity from 20 to 60% [1, 9, 
31, 34]. The sensitivity of cerebral angiography decreases 
along with the caliber of the involved vessels, being most 
sensitive for involvement of large-medium sized vessels. 
Angiography is not exempt of side effects. About 0.8% of 
patients subjected to angiography experience additional neu-
rologic deficits as an adverse event related to the procedure 
[32]. However, given the severity of PACNS and the diffi-
culties in achieving an accurate diagnosis, the risk/ benefit is 
acceptable and conventional angiography is recommended as 
a key diagnostic procedure.  
2.5.2.3. Histopathologic Examination  
  Brain biopsy is considered the gold standard for the diag-
nosis of PACNS but reveals diagnostic histopathologic ab-
normalities in only 50% to 75% of cases [1] (Fig. 1B and C). 
The role of brain biopsy in PACNS is not limited to proving 
inflammation of blood vessels: it is also important to   
excluding other conditions such as infection, malignancy, or 
degenerative diseases for which completely different treat-
ment approaches are required (Table 1) [5, 27].  
  In the largest series of PACNS patients undergoing sur-
gical biopsy, including 43 patients, diagnostic sensitivity of 
brain biopsy was 63% [20]. In this series, the distribution of 
the various morphologic patterns was as follows: acute ne-
crotizing (14%), purely lymphocytic (28%) and granuloma-
tous (58%), with no statistically significant differences in 
disease aggressiveness or response to treatment among them. 
Interestingly, 78% of the biopsies directed to an imaging 
abnormality were diagnostic, whereas none of the blind bi-
opsies demonstrated vasculitis. Biopsies including leptomen-
inges were slightly more sensitive in detecting vasculitis than 
those not including it (58% vs. 40%). In accordance with 
these results other authors have reported a sensitivity of brain 
biopsy around 50% [2, 16]. The high proportion of negative 
biopsies in patients with clinical and radiographic features 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1A). Multiple, non-specific, T2 hyperintense lesions in a 63-
year old patient with suspected primary angiitis of the CNS who 
presented with headache and cognitive impairment. B) Granuloma-
tous pattern of primary angiitis of the central nervous system. 
Transmural inflammation involves a muscular artery of the lepto-
meninges with prominent mononuclear (upper) and granulomatous 
(lower) adventitial inflammation as well as intimal injury with focal 
fibrin thrombus formation (hematoxylin and eosin 20). Courtesy 
of Dr Carlo Salvarani. C) Inflammatory involvement of a small 
vessel. Courtesy of Dr Leonard H Calabrese. D) Multiple areas of 
irregular stenosis and ectasia in a 44year-old patient with biopsy-
proven PACNS. Courtesy of Dr Leonard H Calabrese. 440    Current Neuropharmacology, 2011, Vol. 9, No. 3  Alba et al. 
highly suggestive of PACNS may be explained by the seg-
mental nature of lesions. Moreover biopsies are usually taken 
from the superficial parenchyma and leptomeninges and, in 
some instances, involved vessels are of greater size and are 
located deeper from these areas [20]. To maximize the diag-
nostic sensitivity of the procedure it is recommended that 
biopsies are performed in abnormal areas detected by previ-
ous imaging and include leptomeninges. Stereotactic biopsy 
is recommended for mass lesions only [20, 25]. 
  Occasionally, amyloid deposits can be observed [20, 25]. 
These are more frequently found in samples with a granulo-
matous pattern and those presenting as mass lesions [20, 25]. 
Clinically, patients with amyloid deposits are older and more 
frequently presenting with acute onset and cognitive impair-
ment [39]. Clinical outcome and response to treatment seems 
to be similar to that of patients with no amyloid deposits 
[39]. 
2.5.2.4. Diagnostic Criteria 
  Since histopathologic confirmation of PACNS is not al-
ways feasible, Calabrese and Mallek proposed a series of 
diagnostic criteria combining, clinical, imaging and histopa-
thologic findings [1]. These include: 1) neurologic deficit 
that remains unexplained after a vigorous diagnostic workup, 
including lumbar puncture and neuroimaging studies, 2) an-
giographic abnormalities highly suggestive of vasculitis or 
histopathologic evidence of vasculitis within the CNS and 3) 
no evidence of systemic vasculitis or any other condition to 
which the angiographic or pathologic findings can be attrib-
uted. These conditions are listed in Table 1 (Fig. 2). 
2.5.2.5. Treatment 
  No randomized controlled trials or prospective studies 
have been performed with patients with PACNS. Therefore, 
therapeutic recommendations are based on extrapolation of 
data obtained from trials performed in other severe systemic 
vasculitides, retrospective studies, small case series and ex-
pert opinion [2, 5, 40]. In a retrospective review of treat-
ments received by 101 patients diagnosed with PACNS (70 
by angiography, 31 by biopsy) Salvarani et al. found that 97 
patients were treated with glucocorticosteroids, 25 of them 
with 1gr intravenous methyl-prednisolone pulses and the 
remaining with oral prednisone at a median dose of 60 
mg/day [9]. Forty-nine patients received an immunosuppres-
sive agent: 46 cyclophosphamide (oral at 150 mg/day or in-
travenous at around 1 gr/month) and 3 azathioprine. A favor-
able response was observed in 81% of the patients treated 
with glucocorticoids alone and in 81% of those receiving 
both prednisone and cyclophosphamide. Given the retrospec-
tive nature of the survey it is not possible to conclude that 
immunosuppressive agents are not necessary since the group 
receiving cyclophosphamide may have been considered 
more severe by treating physicians. 
  Treatment with glucocorticoids (oral prednisone or 
equivalent at 60 mg/day preceded by three 1 gr intravenous 
pulses in severe cases) should, then, be started as soon as 
CNS vasculitis (primary or secondary) is clinically suspected 
and infectious diseases reasonably excluded. Prednisone can 
be quickly tapered if the diagnosis is eventually ruled out. 
When the diagnosis of CNS vasculitis is also supported   
by angiography or biopsy and mimics are convincingly   
excluded, cyclophosphamide (oral at 150 mg/day or 1gr 
monthly pulse) is recommended. Pulse intravenous cyclo-
Table 1.  Mimics of Primary Angiitis of the Central Nervous 
System 
INFECTIOUS VASCULITIS 
Viral (HIV, varicella zoster, progressive multifocal leukoencephalopathy) 
Borreliosis 
Tuberculosis 
Syphilis 
Whipple’s disease 
Endocarditis 
INFLAMMATORY DISEASES 
Systemic Vasculitis 
Behçet’s disease 
Neurosarcoidosis 
Systemic lupus erythematosus 
NON-INFLAMMATORY VASCULOPATHIES 
Reversible vasoconstriction syndromes (RVCS) 
Atherosclerosis 
Susac’s syndrome 
Radiation vasculopathy 
Ehlers-Danlos disease 
Kohlmeyer- Degos disease 
Fibromuscular dysplasia 
Fabry’s disease 
Moya-moya disease 
Amyloid angiopathy 
CADASIL 
Pseudoxanthoma elasticum 
Mitochondrial diseases (MELAS) 
DEMYELINATING DISEASES 
Multiple sclerosis 
Acute disseminated encephalomyelitis 
THROMBOEMBOLIC DISEASES 
Antiphospholipid syndrome 
Hypercoagulability states 
Cholesterol embolisms 
Cardiac myxoma 
Nonbacterial thrombotic endocarditis 
MALIGNANCIES 
Multifocal glioma 
CNS lymphoma 
Angiocentric lymphoma 
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phosphamide has equivalent efficacy in inducing remission 
but it is less toxic than daily oral cyclophosphamide in   
systemic vasculitis [40]. By analogy to severe systemic   
vasculitis, switch to a safer immunosuppressive agent 
(azathioprine, methotrexate or mycophenolate) may be   
considered after 4-6 months of cyclophosphamide treatment 
[40-43]. All patients should be given calcium and vitamin  
D, bone protection agents and Pneumocystis infection 
prophylaxis [5]. 
  Recently it has been shown that rituximab is equally ef-
fective than cyclophosphamide in inducing remission in se-
vere ANCA-associated systemic vasculitis [44, 45]. Rituxi-
mab has also been successful in treating SLE patients with 
CNS involvement [46], but there is no experience with ri-
tuximab in PACNS. Two glucocorticoid and cyclophos-
phamide refractory cases responding to TNF blockade have 
been reported [47]. 
  Immunossuppressive treatment should be maintained for 
2-3 years [2, 5]. It is important to keep in mind that about 
25% of patients may relapse [9]. Response to treatment must 
be monitored by periodic neurologic evaluation and serial 
MRI examination every 3-4 months [2, 28]. 
3. REVERSIBLE CEREBRAL VASOCONSTRICTION 
SYNDROME (RCSV) 
  RCVS is a recently proposed term to describe the 
physiopathologic substrate of a group of conditions charac-
terized by prolonged but reversible vasoconstriction of the 
cerebral arteries [48]. Previously, these syndromes were re-
ferred as benign angiopathy of the central nervous system 
and, for many years, there has not been a clear distinction 
between RCVS and true primary angiitis of the CNS. RCVS 
has received a variety of names: Call-Fleming syndrome, 
thunderclap headache with reversible vasospasm, migrainous 
vasospasm or migraine angiitis, postpartum angiopathy, or 
drug-induced cerebral arteritis or angiopathy [48].  
  RCVS may occur spontaneously but in most instances is 
associated with precipitating factors including the use of 
vasoactive substances (i.e. ergotamine derivatives, am-
phetamines and nasal decongestants) other drugs (i.e selec-
tive serotonin-reuptake inhibitors, contraceptives), recrea-
tional drugs (cannabis, ecstasy, LSD, cocaine, alcohol), late 
pregnancy or puerperium, sexual intercourse, and catecho-
lamine producing tumors [48-50]. The most characteristic 
initial clinical manifestation include hyperacute severe and 
recurrent headache that can be associated with neurologic 
symptoms and signs [48].  Headache is usually diffuse al-
though may be also localized, preferentially in the occipital 
Table 2.  Clinical, Laboratory, Imaging and Histopathologic Characteristics Useful to Distinguish RVCS from PACNS 
  RVCS PACNS 
Clinical data 
age 
gender 
trigger (drugs, postpartum etc) 
headache 
cognitive impairment 
 
20-40 years 
primarily women 
frequently identified 
acute and severe 
unusual 
 
40-60 years 
more frequent in men 
absent 
insidious 
frequent 
CSF  Normal or minimal protein increase  Abnormal (increased protein concentration and mild pleocytosis) 
MRI Normal  (>70%)  *  Abnormal in 90%. Small infarcts in grey and white matter in multiple vascular 
territories, diffuse white matter lesions, mass lesions 
Angiography  Abnormal:diffuse areas of multiple 
stenoses and dilatations ** 
May be normal 
Single or multiple abnormalities 
(cut-offs, lumen irregularities, avascular mass lesion) 
CNS / leptomeningeal biopsy  Normal Vasculitis   
* Except when complicated by stroke, intraparenchymal or cortical subarachnoid hemorrhage or posterior reversible leukoencephalopathy. 
** Angiographic abnormalities are required for diagnosis but must be reversible in 6-12 weeks. 
 
 
 
 
 
 
 
 
Fig. (2). Puntiform T2 hyperintense white matter lesions in a 40-
year old woman with Susac’s syndrome. This patient also had sen-
sorineural hypoacusia and bilateral retinal artery branch occlusions 
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area, and may be associated with nausea, vomiting and   
photosensitivity. Other clinical manifestations include visual 
dysfunction, transient ischemic attacks and seizures [48]. 
The major complication of RCVS is stroke that can eventu-
ally lead to permanent sequelae and even death [48, 49].   
Although the pathophysiology of RCVS is not known, the 
prevailing hypothesis considers that there is a transient   
disturbance in the control of cerebral vascular tone [48]. 
  In the largest series reported including 67 patients [49], 
there was a female predominance (67%) with a mean age at 
diagnosis of 42.5±11.8 years (range 19-70 years). Precipitat-
ing factors were identified in 63%, being the use of vasoac-
tive substances the most frequent (55%). The presenting 
symptom in all cases was recent severe headache, and this 
was the only symptom in 76%. Among the 67 patients, 94% 
had multiple thunderclap headaches (mean of 4.5 episodes) 
that recurred over a mean period of 1 week. In this series, 
early complications (within the first week) included cortical 
subarachnoid hemorrhage (22%), reversible posterior leu-
koencephalopathy (9%), intrecerebral bleeding (6%) and 
seizures (3%). Delayed complications (after the first week) 
included transient ischemic attack in 16% and cerebral in-
farcts in 4%. The overall outcome in this series was good, 
with no relapses during a 16±12.4 month follow-up period 
and only 4% of patients had persistent neurological deficits.  
  In the absence of validated diagnostic criteria, Calabrese 
et al. [48] proposed a set of key elements required for the 
diagnosis of RCVS. These include severe, acute headaches, 
with or without additional neurologic signs or symptoms, 
normal or near to normal cerebrospinal fluid analysis, neuro-
imaging tests (transfemoral angiography, CT angiography or 
MRA) documenting multifocal segmental cerebral artery 
vasoconstriction, with no evidence for aneurysmal subarach-
noid hemorrhage, and reversibility of angiographic abnor-
malities within 12 weeks [47-49]. Treatment usually consists 
of calcium-channel blockers [48-51] and brief glucocorticoid 
courses [50, 52].  
  The distinction of PACNS and RVCS is important be-
cause of the different prognosis and treatment requirements. 
Key elements for distinction have been proposed [2, 48] and 
are summarized in Table 2. PACNS typically affects middle-
aged men whereas RVCS is primarily a disease of women 
between 20-40 years. In the latter almost 60% of patients 
report a precipitating event [48], usually exposure to vasoac-
tive substances. Headache in PACNS is indolent and pro-
gressive [9] whereas headache in RVCS is acute and severe 
[2, 48, 49]. Unless complicated by bleeding or infarct, MRI 
does not disclose major changes in RVCS whereas MRI is 
abnormal in 97% of cases with PACNS [9, 50]. By defini-
tion, angiographic abnormalities substantially or completely 
reverse within approximately 3 months.  
4. SYSTEMIC VASCULITIDES INVOLVING THE 
CNS 
  The CNS vasculature can be targeted by systemic vascu-
litis (Table 3). Usually CNS involvement coexists with other 
clearly apparent systemic manifestations but some patients 
may present primarily with prominent symptoms of   
CNS dysfunction [4, 5, 53]. In systemic vasculitis targeting 
small-medium sized vessels, CNS involvement is a predictor 
of poor/guarded prognosis [54, 55] and is one of the factors 
considered to recommend aggressive treatment with cyclo-
phosphamide in addition to high-dose steroids [40, 54, 55]. 
However, in large-vessel vasculitis, CNS involvement may 
benefit from vascular intervention procedures (angioplasty, 
derivative surgery), antiplatelet or anticoagulation treatment 
in addition to high dose glucocorticoids rather than intensifi-
cation of immunossupressive therapy [56-58]. 
Table  3.  Primary Systemic Vasculitis Most Frequently   
Involving the CNS in Adults 
SMALL-MEDIUM VESSEL VASCULITIS(*) 
Wegener’s granulomatosis 
Microscopic polyangiitis 
Churg-Strauss syndrome 
Cryoglobulinemic vasculitis 
Behçet’s disease 
MEDIUM VESSEL VASCULITIS (**) 
Polyarteritis nodosa 
LARGE-VESSEL VASCULITIS 
Giant-cell arteritis 
Takayasu’s arteritis(***) 
In children, Henoch-Shönlein purpura (*) and Kawasaki disease (**) may occasionally 
involve the CNS 
*** Neurologic complications in Takayasu’s arteritis are mainly due to involvement of 
extacranial vessels. 
4.1. CNS Involvement by Small and Medium Sized Vessel 
Vasculitis 
  Globally, cerebrospinal involvement is infrequent in 
small-medium size vessel vasculitis, including Wegener’s 
granulomatosis, microscopic polyangiitis, Churg-Strauss 
syndrome, polyarteritis nodosa, cryoglobulinemic vasculitis, 
and Behçet’s disease. CNS involvement occurs in less than 
15% of patients in most series. 
4.1.1. Wegener Granulomatosis (WG) 
  The prevalence of CNS manifestations in WG ranges 
from 2.7% to 9% in large series of patients [59-61]. Neuro-
logical involvement may account through 3 major mecha-
nisms: vasculitis involving CNS vessels, granulomatous le-
sions located in the brain, meninges or cranial nerves and 
direct extension of destructive granulomatous tissue from 
nasal or paranasal structures [59-62]. 
  Cerebral vasculitis is the most frequent CNS lesion and 
may present with headache, visual disturbances, seizures, 
confusion, ischemic stroke, intracerebral or subarachnoid 
haemorrhage, venous thrombosis or dementia [62, 63]. 
Granulomatous inflammation and thickening of the durama-
ter, pachymeningitis, may present with chronic headache, 
multiple cranial nerve palsies, seizures, meningeal signs, 
encephalopathy, proptosis, limb palsy or ataxia [62-65].   
Pituitary involvement leads to central diabetes insipidus, 
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cies [66]. In these patients, MRI is the image technique of 
choice because it can reveal ischemic or hemorrhagic   
lesions, dural thickening, pituitary involvement or enhance-
ment of inflamed orbital and paranasal mucosa [63]. In   
the case of dural involvement, tissue biopsy may disclose 
granulomatous pachymeningitis [66].  
4.1.2. Microscopic Polyangiitis (MPA) 
  In a series of 85 patients, CNS involvement was present 
in 10 cases (11.8%) and CNS vasculitis was the cause of 
death of one of them [67]. 
  There are only scattered case reports of CNS manifesta-
tions related to MPA in the literature. Multiple bilateral 
cerebral infarctions [68], multiple hemorrhagic infarction of 
the cerebral cortex caused by CNS vasculitis [69], capsular 
warning syndrome and subsequent stroke [70] and pachy-
meningitis have been occasionally reported [71, 72]. 
4.1.3. Churg-Strauss Syndrome (CSS) 
  In the largest published series of CSS patients the CNS is 
reported to be involved in 8% to 14% of patients [73-77].  
  Cerebral infarction is the most frequently reported mani-
festation of CNS involvement [75, 77], probably as result   
of cerebral vasculitis (Fig. 3). Additional less commonly 
reported CNS events include intracerebral haemorrhage   
[78, 79] and pachymeningitis [80, 81]. 
 
 
 
 
 
 
 
 
Fig. (3A). Multiple brain infarcts in a patient with Churg-Strauss 
syndrome. B) CT scan from the same patient disclosing pulmonary 
infiltrates and bilateral pleural effusion. Toracocentesis disclosed 
predominance of eosinophils in pleural fluid exudate. 
4.1.4. Polyarteritis Nodosa (PAN) 
  In a recent series of 348 patients diagnosed with PAN 
over a 42-year period, 4.6% presented with central nervous 
system-related abnormalities [82]. Earlier studies reported a 
higher prevalence, between 15 and 65% [83]. Perhaps in 
present days, earlier recognition of the disease with prompt 
treatment prevents development of severe complications. It 
is important to remark that, widespread ANCA and cryo-
globulin testing has led to re-classification of a substantial 
proportion of patients with necrotizing vasculitis previously 
diagnosed with PAN, which, in fact, has become a much 
more infrequent disease [84].  
    In an extensive literature review, three major clinical 
presentations related to CNS involvement have been recog-
nized in PAN: 1) diffuse encephalopathy characterized by 
cognitive impairment, disorientation or psychosis (8%   
to 20%), 2) seizures (focal or generalized) and 3) focal   
neurologic deficits [83]. Accelerated hypertension may   
also contribute to diffuse encephalopathy in some patients 
[83]. Abnormal findings reported in neuroimaging studies 
(MRI and CTscan) include cerebral infarctions located in the 
brain (cortical or subcortical), cerebellum or brainstem and 
cerebral hemorrhages [85, 86] (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (4A). Hemorrhagic brain infarct in a patient with systemic 
poyarteritis nodosa. This patient also had hypertension, postprandial 
abdominal pain, multineuritis and livedo reticularis. B) Skin biopsy 
of the same patient disclosing necrotizing arteritis in the subcutane-
ous tissue. 
4.1.5. Cryoglobulinemia 
  CNS involvement is uncommon in cryoglobulinemic 
vasculitis. In a retrospective series of 209 patients [87], CNS 
involvement was detected in 3. In a prospective study of 40 
patients with mixed type II cryoglobulinemia vasculitis [88] 
specifically investigating signs of CNS dysfunction, 89% of 
the patients had some cognitive impairment, being attention 
the aspect most commonly altered (70.3%), followed by   
alterations in executive functions and visual construction. 
Whether these abnormalities are due to CNS vasculitis,   
co-morbidities, glucocorticoid, immunosuppressive or anti-
viral treatments or a combination of factors is unclear. 
  Clinical features of CNS involvement in cryoglobuline-
mia include encephalopathy, stroke, transient ischemic   
attacks, lacunar infarctions and hemorrhage [89, 90]. Most  
of the cases reported are associated to hepatitis C virus   
infection. 
4.1.6. Behçet’s Disease 
  The frequency of neurological involvement in Behçet’s 
disease ranges from 5.3% to 14.3% in prospective studies 
[91, 92]. Neuro-Behçet occurs more frequently in patients 
aged 20 to 40 years and is 2-8 times more frequent in men 
than in women. Neurological manifestations commonly   
appear when other systemic features are present. CNS   
involvement is the first disease manifestation in less than   
6% of patients with neuro-Behçet [93]. CNS involvement in 
Behçet’s disease may occur through 2 major mechanisms: 
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  Meningoencephalitis is usually subacute and predomi-
nantly involves the brainstem but may extend to basal gan-
glia, thalamus, cortex and white matter [93, 94]. The spinal 
cord and cranial nerves may also be affected. In the largest 
series of patients with neuro-Behçet [92] the most common 
clinical symptoms were pyramidal signs (96%), hemiparesis 
(60%), behavioural changes, headache and sphincter distur-
bance or impotence. Less common manifestations were 
paraparesis, meningeal signs, movement disorders, brainstem 
signs, seizures, hemianopsia, aphasia, psyachiatric distur-
bances or cerebellar syndrome. CSF analysis was abnormal 
70–80% disclosing moderately elevated protein concentra-
tion and pleocytosis with neutrophilia at early stages [89]. 
MRI discloses hyperintense T2 lesions with contrast en-
hancement and edema. Lesions are usually unilateral and are 
located in the upper brainstem extending towards the thala-
mus and basal ganglia [95]. Tumor-like lesions may occa-
sionally occur [93]. 
  The most common manifestation of vascular neuro-
Behçet is central venous thrombosis with signs and symp-
toms of intracranial hypertension, including papilledema. 
Intracranial aneurysms and ischemic stroke may also occur 
but are infrequent complications. Combined parenchymal 
and vascular involvement may be seen in 20% of patients 
with neuro-Behçet [93]. Patients with neuro-Behçet are 
treated with high-dose glucocorticoids and cyclophos-
phamide. Blocking TNF with infliximab may be useful in 
refractory patients. 
4.2. Large Vessel Vasculitis 
  Both giant-cell arteritis of the elderly and Takayasu dis-
ease may convey CNS involvement. 
4.2.1. Giant Cell Arteritis 
  GCA preferentially targets the cranial vessels. Conse-
quently the most common ischemic complications occur in 
territories supplied by the carotid and vertebral arteries. Al-
though GCA is considered a large to medium sized vessel 
vasculitis, small cranial vessels are frequently affected [96] 
and the most frequent ischemic complication, visual loss, 
derives from involvement of the small arteries supplying   
the optic nerve [97-100]. Visual loss occurs in 15-20% of 
patients [97-100]. In 80-90% of cases visual impairment is 
due to anterior ischemic optic neuritis secondary to involve-
ment of the posterior cilliary arteries supplying the optic 
nerve [101, 102]. Occlusion of the retinal artery is less   
frequent and underlies visual loss in 10% of cases [99, 100].  
  Ischemic stroke or multiinfarct dementia occurs in 3-6% 
of patients and is due to inflammatory involvement of the 
intracranial branches of the carotid and vertebral arteries. 
[97, 100, 103, 104]. When explored, ultrasonography of   
the supraaortic branches are frequently normal [103, 104]. 
Usually, inflammation is limited to the most proximal,   
extradural part of these arteries. In some series, strokes are 
more frequent in the vertebrobasilar territories contrarily   
to atherosclerotic occlusions which are more frequent in   
the carotid branches [103]. Brain infarcts are frequently   
multiple, indicating involvement of various branches,   
reduced flow from proximal stenosis, distant embolization of 
proximal thrombi, or a combination of these [97, 103, 104] 
(Fig. 5A). Although thrombosis is uncommonly seen in tem-
poral artery biopsies, necropsy studies from patients dying 
from GCA-related stroke, frequently disclose thrombosis as 
a precipitating event [100]. Mortality of GCA-related stroke 
is about 30% [103, 104].  
  Stroke is more frequent among individuals with visual 
loss indicating that some individuals may be more prone to 
develop intracranial involvement and related complications 
[97, 98]. Several studies indicate that individuals with 
prominent extracranial large- vessel involvement are less 
prone to develop cranial ischemic complications, suggesting 
heterogeneity in patterns of vascular targeting by GCA [105-
107]. Several studies indicate that traditional vascular risk 
factors are more frequent and the systemic inflammatory 
response is weaker in patients with GCA-related ophthalmic 
and neurologic ischemic complications, making early diag-
nosis and follow up more difficult [97-100, 108]. High dose 
glucocorticoids usually prevent progression of visual im-
pairment. Intravenous methylprednisolone pulses are usually 
administered in this setting but there is no proof that this 
approach is more effective than the standard daily 60 mg 
dose. In 10-27% of patients presenting with visual symp-
toms, vision may continue to deteriorate during the first 1-2 
weeks after the beginning of glucocorticoid treatment [99]. 
Antiplatelet or anticoagulant therapy is usually given in these 
circumstances with variable results [99, 101, 102]. After this 
initial period, the risk of developing subsequent disease-
related visual loss is low, about 1% in 5 years [109]. 
  Stroke frequently occurs during the first weeks after the 
initiation of glucocorticoid treatment. Besides adding antiag-
gregants, anticoagulants, or both, the classical approach to 
this situation has been intensifying glucocorticoid and im-
munosuppressive therapy. However, a recent report indicate 
that some patients with proximal lesions may better benefit 
from intracerebral percutaneous angioplasty [57] (Fig 5B). 
 
 
 
 
 
 
 
 
 
Fig. (5A). Multiple infarcts in the cerebral pons, cerebellum, and 
occipital lobes in a patient with biopsy-proven giant-cell arteritis 
who developed ataxia and cognitive impairment after the initiation 
of glucocorticoid therapy. B) Cerebral angiography displaying   
carotid siphon stenosis in a patient with biopsy-proven giant-cell 
arteritis who developed recurrent transient ischemic attacks (apha-
sia and hemiparesis) in spite of high-dose glucocorticoids, antiplate-
let and anticoagulant therapy. This lesion was successfully treated 
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4.2.2. Takayasu Arteritis 
   Non specific neurologic manifestations such as head-
ache, dizziness of variable intensity, and lightheadedness are 
highly frequent in patients with Takayasu’s arteritis, occur-
ring in 57-90% in most series [58, 110, 111] (Fig. 6). More 
severe complications include visual disturbances or visual 
loss, syncope, transient ischemic attacks and stroke. Most of 
these symptoms/complications can be related to extracranial 
steno-occlusive lesions in the subclavian (with subsequent 
arm-steal syndrome), carotid and vertebral arteries which 
results in decrease brain flow [112, 113]. Stroke occurs in 
less than 10% of cases in large cohorts but it is among the 
leading causes of premature death in these patients [58]. 
Strokes are usually ischemic and secondary thrombosis of 
stenotic vessels with subsequent embolization may be pre-
cipitating events. It is important to remark that cardiomyopa-
thy secondary to aortic valve insufficiency due to aortic root 
dilatation or hypertension occurs in about 10% of patients 
with Takayasu’s disease and may also result in thromboem-
bolic strokes [58]. Hemorrhagic stroke related to hyperten-
sion has also been reported [112]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Multiple stenoses in the carotid and vertebral arteries in  
a 38-year old patient with Takayasu disease complaining from 
lightheadedness and slight dizziness. 
  Intracranial artery involvement seems to be uncommon. 
A recent prospective study using ultrasonography and MRI 
in 17 patients with neurologic symptoms, disclosed signs of 
intracranial involvement in 7 patients [113]. However, no 
angiography was performed and it was not possible to dis-
cern whether these findings were related to vasculitis or pre-
vious embolization. Autopsy studies including the brain are 
scarce in Takayasu’s disease, but intracranial involvement 
seems to be unusual. However, at least one patient with   
vasculitis of intracranial arteries has been reported [114]. 
  Glucocorticoids and in most instances immunossupres-
sive agents are mandatory to induce and maintain remission 
in patients with Takayasu disease. Cyclophosphamide and 
methotrexate have been useful in open-label studies and   
mycophenolate has been also tried in small case series [58, 
110, 115]. Because of its side effects cyclophosphamide is 
usually avoided and other immunosuppressive agents are 
preferred, since Takayasu disease is a relapsing condition 
usually targeting young women [58, 110, 115]. TNF block-
ade has provided benefit to patients refractory to other thera-
pies [116]. Angioplasty, stenting and by-pass surgery are 
very important in the management of severe neurological 
involvement [56, 58]. For better results, revascularization 
procedures, should be avoided, when possible, during peri-
ods of active disease and be performed to patients in remis-
sion [115]. 
CONCLUSIONS 
  CNS vasculitis, either primary or complicating systemic 
vasculitis is uncommon. However CNS involvement is a 
major determinant of severity, morbidity and mortality in 
patients with vasculitis. Diagnosis of PACNS is a challenge 
and requires high index of clinical suspicion. Diagnosis is 
supported by neuroimaging and histologic data but requires 
exclusion of other conditions with the appropriate work-up. 
Neuroimaging techniques are pivotal not only to support the 
diagnosis but also in the follow up of affected patients. 
PACNS or CNS involvement by systemic vasculitis requires 
prompt recognition and aggressive treatment in order to re-
duce mortality and preserve function. 
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